Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (51-60 of 137) with videos related to

Pageof 14
Sort By:
The Journal of Investigative Dermatology|August 7, 2017
Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"Kristian Reich, Craig Leonardi, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
The AWARE study: methodology and baseline characteristicsRobert Bissonnette, Gordon Searles, Ian Landells, et al.
The British Journal of Dermatology|October 23, 2024
Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeksAndrew Blauvelt, Kim Papp, Mona Trivedi, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
International Journal of Dermatology|December 1, 2004
Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitisKim Papp, Doris Staab, John Harper, et al.
Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.
Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.
Cutis|September 15, 2009
A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acneLinda Stein Gold, Jerry Tan, Alma Cruz-Santana, et al.
Lancet (London, England)|July 4, 2012
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialKim Papp, Jennifer C Cather, Les Rosoph, et al.
Dermatology (Basel, Switzerland)|July 15, 2010
Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS TrialKristian Reich, Jean-Paul Ortonne, Urs Kerkmann, et al.
Pageof 14

Showing results (51-60 of 137) with videos related to

Sort By:
Pageof 14
The Journal of Investigative Dermatology|August 7, 2017
Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"Kristian Reich, Craig Leonardi, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
The AWARE study: methodology and baseline characteristicsRobert Bissonnette, Gordon Searles, Ian Landells, et al.
The British Journal of Dermatology|October 23, 2024
Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeksAndrew Blauvelt, Kim Papp, Mona Trivedi, et al.
The New England Journal of Medicine|September 13, 2018
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisKim Papp, Kenneth Gordon, Diamant Thaçi, et al.
International Journal of Dermatology|December 1, 2004
Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitisKim Papp, Doris Staab, John Harper, et al.
Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.
Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.
Cutis|September 15, 2009
A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acneLinda Stein Gold, Jerry Tan, Alma Cruz-Santana, et al.
Lancet (London, England)|July 4, 2012
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialKim Papp, Jennifer C Cather, Les Rosoph, et al.
Dermatology (Basel, Switzerland)|July 15, 2010
Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS TrialKristian Reich, Jean-Paul Ortonne, Urs Kerkmann, et al.
Pageof 14